文献速递神经肿瘤

围术期氨甲环酸用于ACTH分泌型垂体腺瘤的实施方案与试验展望

Perioperative Tranexamic Acid for ACTH-Secreting Pituitary Adenomas: Implementation Protocol Results and Trial Prospectus.
PubMed 文献 · World Neurosurg · 2021-07-03

本研究针对ACTH分泌型垂体腺瘤内镜经鼻切除术,制定围术期氨甲环酸(TXA)机构方案并前瞻性实施。30例患者采用10 mg/kg术前30分钟负荷、2 mg/kg/h维持至术毕的标准化剂量,未发生心肌梗死或术后血栓栓塞事件,主观评估显示术中出血减少。

要点

  • ACTH腺瘤切除术因高血压和皮质醇致血管脆性增加而出血风险高,TXA或可获益。
  • 机构方案:10 mg/kg 30分钟负荷,继以2 mg/kg/h维持至手术结束。
  • 30例实施中无心肌梗死或术后血栓栓塞事件,需谨慎术前筛选。

核心结论

  • 围术期TXA可能是控制ACTH分泌型垂体腺瘤内镜经鼻切除术中出血的有效方法。
  • 在审慎选择患者的前提下,初始经验显示该机构方案风险/获益比良好。

研究设计与样本

  • 制定机构围术期TXA给药方案并前瞻性研究其实施情况。
  • 术前TXA标准由年龄、病史和危险因素定义。
  • 30例符合纳入标准并接受围术期TXA的患者纳入描述性统计。

主要发现

  • 30例患者采用标准化剂量:切皮前30分钟10 mg/kg负荷,术中2 mg/kg/h维持。
  • 未观察到心肌梗死或术后血栓栓塞事件。
  • 主观评估显示对患者选择方案满意,术中出血程度有意义的减少。

关键数值与推荐

  • TXA剂量方案:切皮前30分钟10 mg/kg负荷,维持2 mg/kg/h至手术结束。
  • 术前TXA标准基于年龄、病史和危险因素。

临床怎么用

  • 对ACTH分泌型垂体腺瘤内镜经鼻切除术患者,可考虑围术期TXA以减少术中出血。
  • 实施前需按年龄、病史和危险因素严格筛选患者,警惕血栓栓塞风险。

局限性

  • 为单机构前瞻性实施研究,样本量30例,描述性统计。
  • 术中出血减少基于主观评估。
  • TXA在该人群的潜在获益此前未经研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Primary resection of adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma has become a front-line standard-of-care treatment for Cushing disease. However, surgical intervention can be challenging because of elevated blood pressure, as well as direct cortisol impacts on endothelial cells, vascular permeability, and tissue friability-potentially resulting in increased intraoperative bleeding. Tranexamic acid (TXA) is a well-studied, widely used intravenous hemostatic; however, the potential benefit during resection of ACTH-secreting pituitary adenoma is unstudied. The purpose of this study was to define an institutional protocol for perioperative administration of TXA in patients undergoing endoscopic endonasal approach for resection of ACTH-secreting pituitary adenoma, and to study the implementation of our novel protocol in a prospective fashion. METHODS: Criteria for preoperative TXA were defined by age, medical history, and risk factors. Descriptive statistics were reported for all patients receiving perioperative TXA. RESULTS: Thirty patients met inclusion criteria and underwent perioperative administration of TXA, using a standardized dosing protocol of a 10 mg/kg bolus in 30 minutes prior to incision, followed by maintenance infusion of 2 mg/kg/hour for the duration of the procedure. No incidence of myocardial infarction or postoperative thromboembolic events were noted. Subjective assessments indicated satisfaction with the patient selection protocol, and meaningful reduction in the extent of intraoperative bleeding. CONCLUSIONS: Perioperative TXA represents a potentially efficacious approach for control of intraoperative bleeding during endonasal resection of ACTH-secreting tumors. Careful preoperative patient selection is emphasized, given the potential for thromboembolic complications; however, initial experience with our institutional protocol suggests a favorable risk/benefit profile when this treatment is applied judiciously.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Graffeo CS, Carlstrom LP, Cohen SC, et al. Perioperative Tranexamic Acid for ACTH-Secreting Pituitary Adenomas: Implementation Protocol Results and Trial Prospectus. World Neurosurg. 2021. PMID: 34229096. doi:10.1016/j.wneu.2021.06.111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。